New Study Reveals Our Skin’s Own Bacteria Can Help Protect Us From the Bad Effects of Sunlight

The skin microbiome plays an important role in health and disease. Researchers have now substantiated that certain skin bacteria can protect us from the sun’s ultraviolet (UV) radiation specifically by metabolizing cis-urocanic acid using an enzyme called urocanase. This enables the skin's ability to fine-tune how it responds to UV radiation The findings of the study se abre en una nueva pestaña/ventana in the Journal of Investigative Dermatology se abre en una nueva pestaña/ventana, published by Elsevier, provide a striking case study that demonstrates the ability of the skin microbiome to remodel host immune functions.

The skin hosts a vast ecosystem composed of millions of microorganisms, including bacteria, fungi, and viruses. The composition of the cutaneous microbiome is highly unique, complex, and varies greatly depending on the anatomical location. Commensal microbes, also known as normal microbiota or indigenous microbiota that live in a beneficial or neutral relationship without causing harm, adapt their metabolism to the resources available in their microenvironment, feeding on our skin's nutrients and producing various molecules that affect their environment and interact with our skin cells.

Lead investigator VijayKumar Patra, PhD, Centre International de Recherche en Infectiologie; Lyon, France, and Research Unit for Photodermatology, Medical University of Graz, Austria, explains, "To date, many internal and external factors have been identified that influence the composition of the skin microbiome. These include various individual parameters such as race, gender, age, hormone levels, diet, and hygiene, but environmental factors and the effects of occupation, pollution, and climate also have a major influence. We have known for a long time that UV radiation modulates immune responses directed against environmental antigens on the surface of the skin and, more recently, that the skin microbiome also plays a role in regulating these responses. What intrigued us was the idea that certain microbes could be actively involved in or even interfere with UV effects. The overlap between microbial metabolism and host immunity became the focus of our investigation."

Researchers used a combination of microbiome sequencing, immunological assays, in vitro cultures, and gnotobiotic mouse models, in which all microorganisms present are defined, to study how skin bacteria respond to UVB radiation, the type of UV radiation that typically causes sunburn. They discovered that certain skin bacteria specifically metabolize cis-urocanic acid, a photoproduct of a major UV-absorbing chromophore of the stratum corneum, trans-urocanic acid, using an enzyme called urocanase. Compared to trans-urocanic acid, cis-urocanic acid is endowed with potent immunomodulatory properties. This microbial metabolism then limits the ability of cis-urocanic acid to inhibit immune responses, which means that skin bacteria fine-tune our skin's response to UV radiation.

The researchers point out the intriguing interplay between sunscreens, cis-urocanic acid, and the microbiome with each other, competing in and on the stratum corneum, as the most superficial layer of the skin.

Co-investigator Marc Vocanson, PhD, Centre International de Recherche en Infectiologie, Lyon, France, notes, "This is the first time we have demonstrated a direct metabolic link between UV radiation, a host-derived molecule, and bacterial behavior that affects immune function. As interest grows in both microbiome research and personalized medicine, understanding these microbe-host interactions could reshape the way we think about sun protection, immune diseases, skin cancer, or even treatments like phototherapy."

Co-investigator Peter Wolf, MD, Research Unit for Photodermatology, Medical University of Graz, Austria, concludes, "These findings open the door to microbiome-aware sun protection, where we not only protect the skin from UV radiation, but also consider how resident microbes can alter the immune landscape after exposure. In the future, topical treatments that modulate microbial metabolism could be used to minimize, maintain, or enhance UV-induced immunosuppression when clinically beneficial, such as with phototherapy."

Commenting on the findings, noted expert in the field Anna Di Nardo, MD, PhD, University of California San Diego, and San Gallicano Dermatological Institute IRCCS, Rome, says, “This pivotal study shows that microbial communities are not passive victims of environmental stress but dynamic regulators of immune responses, capable of metabolizing UV-induced skin products such as cis-urocanic acid. This newly uncovered role of microbial metabolism in modulating UV tolerance reshapes our understanding of the skin barrier — not just as a structural shield but as a metabolically active, microbially regulated interface. With increasing concerns about UV exposure, skin aging, and cancer, a deeper understanding of this axis offers promising avenues for therapy and prevention.”

Notes for editors

The article is “Urocanase-Positive Skin-Resident Bacteria Metabolize cis-Urocanic Acid and in Turn Reduce the Immunosuppressive Properties of UVR,” by VijayKumar Patra, Slave Trajanoski, Aaroh Joshi, Vanina Lenief, Chloe Goyet, Altan Cornu, Nicole Golob-Schwarzl, Meghana Somlapura, Amandine Mosnier, Maximilian Zarfl, Thomas Eichmann, Harald Köfeler, Mary Norval, Jean-Francois Nicolas, Peter Wolf, and Marc Vocanson (https://doi.org/10.1016/j.jid.2025.03.035 se abre en una nueva pestaña/ventana). It appears online in the Journal of Investigative Dermatology, published by Elsevier.

The article is openly available for 60 days at https://www.jidonline.org/article/S0022-202X(25)00405-1 se abre en una nueva pestaña/ventana.

The full text of the article is also available to credentialed journalists upon request; contact Theresa Monturano at +1 215 239 3711 or [email protected] se abre en una nueva pestaña/ventana. Journalists wishing to interview the authors should contact VijayKumar Patra, PhD, at [email protected] se abre en una nueva pestaña/ventana, Marc Vocanson, PhD, at [email protected] se abre en una nueva pestaña/ventana, or Peter Wolf, MD, at [email protected] se abre en una nueva pestaña/ventana.

About the Journal of Investigative Dermatology

The Journal of Investigative Dermatology  se abre en una nueva pestaña/ventana(JID) is the official journal of the Society of Investigative Dermatology and the European Society for Dermatological Research. JID publishes high impact reports describing original research related to all aspects of cutaneous biology and skin diseases. Descriptions of important findings that result from basic, translational, or clinical research are published. Clinical research can include, but is not limited to, interventional trials, genetics studies, epidemiology, and health services research. www.jidonline.org  se abre en una nueva pestaña/ventana

Acerca de Elsevier

Como líder mundial en información y análisis científicos, Elsevier ayuda a los investigadores y profesionales de la salud a hacer avanzar la ciencia y mejorar los resultados de salud en beneficio de la sociedad. Lo hacemos facilitando conocimientos y la toma de decisiones críticas con soluciones innovadoras basadas en contenido confiable y basado en evidencia y tecnologías digitales avanzadas habilitadas por IA. Hemos apoyado el trabajo de nuestras comunidades de investigación y atención médica durante más de 140 años. Nuestros 9500 empleados en todo el mundo, incluidos 2300 tecnólogos, se dedican a apoyar a investigadores, bibliotecarios, líderes académicos, financiadores, gobiernos, empresas intensivas en I+D, médicos, enfermeras, futuros profesionales de la salud y educadores en su trabajo crítico. Nuestras 2900 revistas científicas y libros de referencia icónicos incluyen los títulos más importantes en sus campos, incluidos Cell Press, The Lancet y Gray's Anatomy. Junto con Elsevier Foundation se abre en una nueva pestaña/ventana, trabajamos en asociación con las comunidades a las que servimos para promover la inclusión y la diversidad en la ciencia, la investigación y la atención médica en los países en desarrollo y en todo el mundo. Elsevier es parte de RELX, un proveedor global de herramientas de toma de decisiones y análisis basados ​​en información para clientes profesionales y comerciales. Para obtener más información sobre nuestro trabajo, soluciones digitales y contenido, visite www.elsevier.com.